Neuroprotective strategies in Parkinson's disease: An update on progress

CNS Drugs

Volumn 17, Issue 10, 2003, Pages 729-762

  Mandel, Silvia ^a   Grünblatt, Edna ^b   Riederer, Peter ^b   Gerlach, Manfred ^b   Levites, Yona ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; AMANTADINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; APOMORPHINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DEFEROXAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N(G) NITROARGININE METHYL ESTER; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; NITRIC OXIDE SYNTHASE; OXIDOPAMINE; PRAMIPEXOLE; RASAGILINE; SELEGILINE; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

APOPTOSIS; DRUG MECHANISM; DRUG RESEARCH; HUMAN; NERVE CELL DEGENERATION; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHYTOTHERAPY; TREATMENT OUTCOME;

EID: 0041731997     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317100-00004     Document Type: Review

References (336)

1. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977; I (8007): 345-9
2. Lindvall O, Backlund EO, Farde L, et al. Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen. Ann Neurol 1987; 22 (4): 457-68
3. Freeman TB, Olanow CW, Hauser RA, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995; 38 (3): 379-88
4. Barker RA. Prospects for the treatment of Parkinson's disease using neural grafts. Expert Opin Pharmacother 2000; 1 (5): 889-902
5. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344 (10): 710-9
6. Parboosingh JS, Rousseau M, Rogan F, et al. Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. Arch Neurol 1995; 52 (12): 1160-3
7. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276 (5321): 2045-7
8. Polymeropoulos MH. Autosomal dominant Parkinson's disease and alpha-synuclein. Ann Neurol 1998; 44 (3 Suppl. 1): S63-4
9. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998; 4 (11): 1318-20
10. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388 (6645): 839-40
11. Chung KK, Dawson VL, Dawson TM. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci 2001; 24 (11 Suppl.): S7-14
12. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392 (6676): 605-8
13. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25 (3): 302-5
14. Polymeropoulos MH. Genetics of Parkinson's disease. Ann N Y Acad Sci 2000; 920: 28-32
15. Linazasoro G. Neuroprotection in Parkinson's disease: love story or mission impossible? Exp Rev Neurotherapeutics 2002; 2 (3): 403-16
16. McNaught KS, Belizaire R, Jenner P, et al. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 2002; 326 (3): 155-8
17. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989; 52 (2): 515-20
18. Youdim MB, Ben-Shachar D, Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 1993; 8 (1): 1-12
19. Gotz ME, Kunig G, Riederer P, et al. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 1994; 63 (1): 37-122
20. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996; 47 (0028-3878): 161-70
21. Olanow CW, Youdim MB. Iron and neurodegeneration: prospects for neuroprotection. In: Olanow CW, Jenner P, Youdim MB, editors. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press, 1996: 55-69
22. Youdim MBH, Riederer P. Understanding Parkinson's disease. Sci Am 1999; 276 (1): 52-9
23. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 1998; 13 (0885-3185): 24-34
24. Mandel S, Grünblatt E, Youdim MBH. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J Neural Transm Suppl 2000; 60: 117-24
25. Mendez JS, Finn BW. Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats. J Neurosurg 1975; 42 (2): 166-73
26. Kostrzewa RM, Harper JW. Effect of 6-hydroxydopa on catecholamine-containing neurons in brains of newborn rats. Brain Res 1974; 69 (1): 174-81
27. Burns RS, Chiueh CC, Markey SP, et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 1983; 80 (14): 4546-50
28. Chiueh CC, Miyake H, Peng MT. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv Neurol 1993; 60: 251-8
29. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979; 1 (3): 249-54
30. Heikkila RE, Manzino L, Cabbat FS, et al. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984; 311 (5985): 467-9
31. Tatton WG. Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 1993; 8 Suppl. 1: S20-30
32. Santiago M, Matarredona ER, Granero L, et al. Neuroprotective effect of the iron chelator desferrioxamine against MPP+ toxicity on striatal dopaminergic terminals. J Neurochem 1997; 68 (2): 732-8
33. Lan J, Jiang DH. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transmission 1997; 104 (4-5): 469-81
34. Matarredona ER, Santiago M, Cano J, et al. Involvement of iron in MPP+ toxicity in substantia nigra: protection by desferrioxamine. Brain Res 1997; 773 (1-2): 76-81
35. Ben-Shachar D, Eshel G, Finberg JP, et al. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 1991; 56 (4): 1441-4
36. Cadet JL, Katz M, Jackson-Lewis V, et al. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 1989; 476 (1): 10-5
37. Perumal AS, Gopal VB, Tordzro WK, et al. Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 1992; 29 (5): 699-701
38. Gassen M, Gross A, Youdim MB. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord 1998; 13 (2): 242-8
39. Grünblatt E, Mandel S, Berkuzki T, et al. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 1999; 14 (4): 612-8
40. Grünblatt E, Mandel S, Maor G, et al. Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal doamine neuronal loss. J Neurochem 2001; 77 (1): 146-56
41. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998; 12 (10): 905-12
42. Di Monte D, Sandy MS, Smith MT. Increased efflux rather than oxidation is the mechanism of glutathione depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Biophys Res Commun 1987; 148 (1): 153-60
43. Przedborski S, Jackson-Lewis V, Yokoyama R, et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 1996; 93 (10): 4565-71
44. Schulz JB, Matthews RT, Muqit MM, et al. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995; 64 (2): 936-9
45. DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996; 14 (4): 457-60
46. Lee CK, Klopp RG, Weindruch R, et al. Gene expression profile of aging and its retardation by caloric restriction. Science 1999; 285 (5432): 1390-3
47. Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature 2000; 405 (6788): 827-36
48. Mandel S, Grünblatt E, Maor G, et al. Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem Res 2002; 27 (10): 1231-43
49. Grünblatt E, Mandel S, Maor G, et al. Gene expression analysis in MPTP mice model of Parkinson's disease using cDNA microarray. J Neurochem 2001; 78: 1-12
50. Cadet JL, Jayanthi S, McCoy MT, et al. Temporal profiling of methamphetamine-induced changes in gene expression in the mouse brain: evidence from cDNA array. Synapse 2001; 41 (1): 40-8
51. Xie T, Tong L, Barrett T, et al. Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity. J Neurosci 2002; 22 (1): 274-83
52. Berding G, Odin P, Brooks DJ, et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord 2001; 16 (6): 1014-22
53. Napolitano M, Centonze D, Calce A, et al. Experimental Parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum. Neurobiol Dis 2002; 10 (3): 387-95
54. Smyth PG, Berman SA. Markers of apoptosis: methods for elucidating the mechanism of apoptotic cell death from the nervous system. Biotechniques 2002; 32 (3): 648-50, 652, 654 passim
55. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000; 1 (2): 120-9
56. Blum D, Torch S, Lambeng N, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001; 65 (2): 135-72
57. Jimenez Del Rio M, Velez Pardo C. Apoptosis in neurodegenerative diseases: facts and controversies. Rev Neurol 2001; 32 (9): 851-60
58. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968; 17 (7): 1285-97
59. Youdim MBH, Gross A, Finberg JPM. Rasagiline [N-propargyl-IR (+)-aminoindant], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001; 132: 500-6
60. Riederer P, Youdim MBH, Rausch WD, et al. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm 1978; 43 (3-4): 217-26
61. Sonsalla PK, Golbe LI. Deprenyl as prophylaxis against Parkinson's disease? Clin Neuropharmacol 1988; 11 (6): 500-11
62. Knoll J, Ecseri Z, Kelemen K, et al. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965; 155: 154-64
63. Magyar K, Vizi ES, Ecseri Z, et al. Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methylpropinylamine (E-250). Acta Physiol Acad Sci Hung 1967; 32 (4): 377-87
64. Varga E, Tringer L. Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinylHCI, "E-250"). Acta Med Acad Sci Hung 1967; 23 (3): 289-95
65. Birkmayer W, Riederer P, Youdim MBH, et al. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenil. J Neural Transm 1975; 36 (3-4): 303-26
66. Presthus J, Hajba A. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease. Acta Neurol Scand Suppl 1983; 95: 127-33
67. Robertson DR, George CF. Drug therapy for Parkinson's disease in the elderly. Br Med Bull 1990; 46 (1): 124-46
68. Mendlewicz J, Youdim MBH. A selective MAO-B inhibitor (L-deprenyl) and 5-HTP as antidepressant therapy. In: Youdim MBH, Paykel ES, editor. Monoamine oxidase inhibitors: the state of the art. London: John Wiley & Sons Ltd, 1981: 177-88
69. Golbe LI. Deprenyl as symptomatic therapy in Parkinson's disease. Clin Neuropharmacol 1988; 11 (5): 387-400
70. Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 1985; 64 (2): 113-27
71. Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989; 26 (5): 689-90
72. Oreland L, Gottfries CG. Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10 (3-5): 533-40
73. Fowler CJ, Wiberg A, Oreland L, et al. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 1980; 49 (1-2): 1-20
74. Glover V, Gibb C, Sandler M. The role of MAO in MPTP toxicity: a review. J Neural Transm Suppl 1986; 20: 65-76
75. Knoll J. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J Neural Transm Suppl 1993; 40: 69-91
76. Carrillo MC, Minami C, Kitani K, et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 2000; 67 (5): 577-85
77. Kitani K, Minami C, Isobe K, et al. Why (-)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech Ageing Dev 2002; 123 (8): 1087-100
78. Lai CT, Zuo DM, Yu PH. Is brain superoxide dismutase activity increased following chronic treatment with 1-deprenyl? J Neural Transm Suppl 1994; 41: 221-9
79. Langston JW. Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies. Neurology 1990; 40 (10 Suppl. 3): Suppl. 61-6
80. Magyar K. Behaviour of (-)-deprenyl and its analogues. J Neural Transm Suppl 1994; 41: 167-75
81. Lamensdorf I, Porat S, Simantov R, et al. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Br J Pharmacol 1999; 126 (4): 997-1002
82. Tatton WG, Wadia JS, Ju WY, et al. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl 1996; 48: 45-59
83. Maruyama W, Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev 1999; 111 (2-3): 189-200
84. Maruyama W, Yamamoto T, Kitani K, et al. Mechanism underlying anti-apoptotic activity of a (-) deprenyl-related propargylamine, rasagiline. Mech Ageing Dev 2000; 116 (2-3): 181-91
85. Mizuta I, Ohta M, Ohta K, et al. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 2000; 279 (3): 751-5
86. Group TPS. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328 (3): 176-83
87. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38 (5): 771-7
88. Chiba K, Trevor A, Castagnoli Jr N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984; 120 (2): 574-8
89. Finnegan KT, Skratt JJ, Irwin I, et al. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur J Pharmacol 1990; 184 (1): 119-26
90. Wu RM, Murphy DL, Chiueh CC. Neuronal protective and rescue effects of deprenyl against MPP+ dopaminergic toxicity. J Neural Transm Gen Sect 1995; 100 (1): 53-61
91. Salonen T, Haapalinna A, Heinonen E, et al. Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity. Acta Neuropathol (Berl) 1996; 91 (5): 466-74
92. Sprague JE, Nichols DE. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther 1995; 273 (2): 667-73
93. Chiueh CC, Huang SJ, Murphy DL. Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse 1992; 11 (4): 346-8
94. Wu RM, Murphy DL, Chiueh CC. Suppression of hydroxyl radical formation and protection of nigral neurons by 1-deprenyl (selegiline). Ann N Y Acad Sci 1996; 786: 379-90
95. Carrillo MC, Kitani K, Kanai S, et al. (-)Deprenyl increases activities of superoxide dismutase and catalase in certain brain regions in old male mice. Life Sci 1994; 54 (14): 975-81
96. Tatton WG, Olanow CW. Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochim Biophys Acta 1999; 1410 (2): 195-213
97. Knoll J, Dallo J, Yen TT. Striatal dopamine, sexual activity and lifespan: longevity of rats treated with (-)deprenyl. Life Sci 1989; 45 (6): 525-31
98. Kitani K, Kanai S, Sato Y, et al. Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats: further evidence. Life Sci 1993; 52 (3): 281-8
99. Birkmayer W, Birkmayer GD. Effect of (-)deprenyl in long-term treatment of Parkinson's disease: a 10-years experience. J Neural Transm Suppl 1986; 22: 219-25
100. Group PS. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol 1995; 52 (3): 237-45
101. Group PS. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998; 43 (3): 318-25
102. Kalir A, Sabbagh A, Youdim MBH. Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 1981; 73 (1): 55-64
103. Finberg JPM, Tenne M, Youdim MBH. Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. In: Youdim MBH, Peykel ES, editors. Monoamine oxidase inhibitors: the state of the art. Chichester: Wiley, 1981: 31-41
104. Finberg JP, Lamensdorf I, Weinstock M, et al. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 1999; 80: 495-9
105. Maruyama W, Akao Y, Youdim MBH, et al. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1 (R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm Suppl 2000; 60: 171-86
106. Maruyama W, Akao Y, Youdim MBH, et al. Transfection-enforced bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl (R)salsolinol. J Neurochem 2001; 78: 727-35
107. Huang W, Chen Y, Shohami E, et al. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 1999; 366 (2-3): 127-35
108. Youdim MBH, Wadia JS, Tatton NA. Neuroprotective properties of the antiparkinson drug rasagiline and its optical S-isomer [letter]. Neurosci Lett 1999; 54: S45
109. Goggi J, Theofilopoulos S, Riaz SS, et al. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. Neuroreport 2000; 11 (18): 3937-41
110. Oh C, Murray B, Bhattacharya N, et al. (-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. J Neurosci Res 1994; 38 (1): 64-74
111. Abu-Raya S, Tabakman R, Blaugrund E, et al. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 2002; 434 (3): 109-16
112. Youdim MBH, Wadia A, Tatton NA, et al. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 2001; 939: 450-8
113. Yogev-Falach M, Amit T, Bar-Am O, et al. The involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 2002; 16: 1674-6
114. Youdim MBH, Weinstock M. Molecular basis of neuroprotective activities of rasagline and the anti-Alzheimer drug TV3326, [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol 2002; 21 (6): 555-73
115. Maruyama W, Weinstock M, Youdim MB, et al. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-3(R)aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 2003 May 8; 341 (3): 233-6
116. Maruyama W, Akao Y, Carrillo MC, et al. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002; 24 (5): 675-82
117. Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000; 23 (6): 324-30
118. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59 (12): 1937-43
119. Shoulson I. Results of the TEMPO trial. Efficacy and safety of rasagiline as monotherapy: 12 month data. Parkinson Study Group. The 7th International Congress of Parkinson's Disease and Movement Disorders; 2002 Nov 10; Miami
120. Uitti RJ, Alskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996; 5 (5): 369-88
121. Gerlach M, Ben-Shachar D, Riederer P, et al. Altered brain metabolism of iron as a cause of neurodegenerative diseases?. J Neurochem 1994; 63 (3): 793-807
122. Gassen M, Glinka Y, Pinchasi B, et al. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 1996; 308 (2): 219-25
123. Nishibayashi S, Asanuma M, Kohno M, et al. Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 1996; 67 (5): 2208-11
124. Cassarino DS, Fall CP, Smith TS, et al. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 1998; 71 (1): 295-301
125. Youdim MB, Gassen M, Gross A, et al. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. J Neural Transm Suppl 2000; 58: 83-96
126. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 1998; 44 (3 Suppl. 1): S167-74
127. Zou L, Jankovic J, Rowe DB, et al. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci 1999; 64 (15): 1275-85
128. Bennett JP, Carvey PM, Hinds TR, et al. Mechanisms of action of pramipexole putative neuroprotective effects. In: Johnson S, Johnson FN, editors. Contemporary pharmacotherapy. Lancashire: Marius Press, 2001: 33-57
129. Mena MA, Davila V, Bogaluvsky J, et al. A synergistic neurotrophic response to 1-dihydroxyphenylalanine and nerve growth factor. Mol Pharmacol 1998; 54 (4): 678-86
130. Ohta M, Mizuta I, Ohta K, et al. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 2000; 272 (1): 18-22
131. Hall ED, Andrus PK, Oostveen JA, et al. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 1996; 742 (1-2): 80-8
132. Kondo T, Ito T, Sugita Y. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann N Y Acad Sci 1994; 738: 222-9
133. Linazasoro G. Subcutaneous apomorphine in the treatment of Parkinson's disease. Neurologia 1994; 9 (1): 1-3
134. Fornai F, Battaglia G, Gesi M, et al. Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res 2001; 898 (1): 27-35
135. Iida M, Miyazaki I, Tanaka K, et al. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999; 838 (1-2): 51-9
136. Zou L, Xu J, Jankovic J, et al. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett 2000; 281 (2-3): 167-70
137. Iida M, Miyazaki I, Tanaka K, et al. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999; 838 (1-2): 51-9
138. Sam EE, Verbeke N. Free radical scavenging properties of apomorphine enantiomers and dopamine: possible implication in their mechanism of action in parkinsonism. J Neural Transm Park Dis Dement Sect 1995; 10 (2-3): 115-27
139. Ubeda A, Montesinos C, Paya M, et al. Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines. Free Radic Biol Med 1993; 15 (2): 159-67
140. Gassen M, Youdim MBH. Free radical scavengers: chemical concepts and clinical relevance. J Neural Transm Suppl 1999; 56: 193-210
141. Sawada H, Ibi M, Kihara T, et al. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 1998; 44 (1): 110-9
142. Takashima H, Tsujihata M, Kishikawa M, et al. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2) receptors. Exp Neurol 1999; 159 (1): 98-104
143. Carvey PM, Ling ZD, Sortwell CE, et al. A clonal line of mesencephalic progenitor ceils converted to dopamine neurons by hematopoietic cytokines: a source of cells for transplantation in Parkinson's disease. Exp Neurol 2001; 171 (1): 98-108
144. Le W, Jankovic J, Xie W, et al. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 2000; 107 (10): 1165-73
145. Kitamura Y, Kosaka T, Kakimura JI, et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y ceils. Mol Pharmacol 1998; 54 (6): 1046-54
146. Abramova NA, Cassarino DS, Khan SM, et al. Inhibition by R (+) or S (-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res 2002; 67 (4): 494-500
147. Weinreb O, Mandel S, Youdim MBH. cDNA gene expression profile homology of antioxidants and their anti-apoptotic and pro-apoptotic activities in human neuroblastoma cells. FASEB J 2003; 17: 935-7
148. Marek K, Seibyl J, Shoulson I, et al. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287 (13): 1653-61
149. Whone A, Remy P, Davis MR, et al. The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa [abstract]. Neurology 2002; 58: A82-3
150. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981; 44 (11): 1020-3
151. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995; 45 (3 Suppl. 3): S13-21
152. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia: implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990; 13 (7): 272-6
153. Kornhuber J, Bormann J, Retz W, et al. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Ear J Pharmacol 1989; 166 (3): 589-90
154. Riederer P, Lange KW, Kornhuber J, et al. Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosis. J Neural Transm Suppl 1991; 34: 203-10
155. Starr MS. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 1995; 19 (4): 264-93
156. Klockgether T, Turski L. Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann Neurol 1993; 34 (4): 585-93
157. Choi DW. Excitotoxic cell death. J Neurobiol 1992; 23 (9): 1261-76
158. Small DL, Buchan AM. NMDA antagonists: their role in neuroprotection. Int Rev Neurobiol 1997; 40: 137-71
159. McGeer PL, Itagaki S, McGeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol 1988; 76 (6): 550-7
160. Jellinger K, Paulus W, Grundke-Iqbal I, et al. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 1990; 2: 327-40
161. Mogi M, Harada M, Kondo T, et al. Interleukin- 1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994; 180 (2): 147-50
162. Mogi M, Harada M, Kondo T, et al. Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1995; 9 (1): 87-92
163. Mogi M, Harada M, Narabayashi H, et al. Interleukin (IL)-I beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 1996; 211 (0304-3940): 13-6
164. Mogi M, Harada M, Riederer P, et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994; 165 (1-2): 208-10
165. Blum-Degen D, Muller T, Kuhn W, et al. Interleukin- 1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995; 202 (1-2): 17-20
166. Katsuura G, Gottschall PE, Dahl RR, et al. Interleukin-1 beta increases prostaglandin E2 in rat astrocyte cultures: modulatory effect of neuropeptides. Endocrinology 1989; 124 (6): 3125-7
167. Bezzi P, Carmignoto G, Pasti L, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998; 391 (6664): 281-5
168. Robinson MB, Djali S, Buchhalter JR. Inhibition of glutamate uptake with L-trans-pyrrolidine-2,4-dicarboxylate potentiates glutamate toxicity in primary hippocampal cultures. J Neurochem 1993; 61 (6): 2099-103
169. Rothstein JD, Jin L, Dykes-Hoberg M, et al. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A 1993; 90 (14): 6591-5
170. Schwab RS, England Jr AC, Poskanzer DC, et al. Amantadine in the treatment of Parkinson's disease. JAMA 1969; 208 (7): 1168-70
171. Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of 1-adamantanamine (amantadine). Science 1964; 144: 862-3
172. Nastuk WL, Su P, Doubilet P. Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 1976; 264 (5581): 76-9
173. Gianutsos G, Chute S, Dunn JP. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol 1985; 110 (3): 357-61
174. Kornhuber J, Mack-Burkhardt F, Riederer P, et al. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 1989; 77 (2-3): 231-6
175. Chen HS, Pellegrini JW, Aggarwal SK, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992; 12 (11): 4427-36
176. Lustig HS, Ahem KV, Greenberg DA. Antiparkinsonian drugs and in vitro excitotoxicity. Brain Res 1992; 597 (1): 148-50
177. Rojas P, Altagracia M, Kravsov J, et al. Partially protective effect of
178. Schwab RS, Poskanzer DC, England Jr AC, et al. Amantadine in Parkinson's disease: review of more than two years' experience. JAMA 1972; 222 (7): 792-5
179. Dallos V, Heathfield K, Stone P, et al. Use of amantadine in Parkinson's disease: results of a double-blind trial. BMJ 1970; 4 (726): 24-6
180. Mann DC, Pearce LA, Waterbury LD. Amantadine for Parkinson's disease. Neurology 1971; 21 (9): 958-62
181. Parkes JD, Baxter RC, Curzon G, et al. Treatment of Parkinson's disease with amantadine and levodopa: a one-year study. Lancet 1971; I (7709): 1083-6
182. Fahn S, Isgreen WP. Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses. Neurology 1975; 25 (8): 695-700
183. Savery F. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease. Dis Nerv Syst 1977; 38 (8): 605-8
184. Luginger E, Wenning GK, Bosch S, et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000; 15 (5): 873-8
185. Snow BJ, Macdonald L, McAuley D, et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000; 23 (2): 82-5
186. Del Dotto P, Pavese N, Gambaccini G, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 2001; 16 (3): 515-20
187. Paci C, Thomas A, Onofrj M. Amantadine for dyskinesia in patients affected by severe Parkinson's disease. Neurol Sci 2001; 22 (1): 75-6
188. Gerlach M, Riederer PF. Time sequences of dopaminergic cell death in Parkinson's disease: indications for neuroprotective studies. Adv Neurol 1999; 80: 219-25
189. Wilson JA, Farquhar DL, Primrose WR, et al. Long term amantadine treatment: the danger of withdrawal. Scott Med J 1987; 32 (5): 135
190. Danielczyk W. Therapy of akinetic crises. Med Welt 1973; 24 (33): 1278-82
191. Uitti RJ. More recent lessons from amantadine [letter]. Neurology 1999; 52 (3): 676
192. Seif el Nasr M, Peruche B, Rossberg C, et al. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 1990; 185 (1): 19-24
193. Kornhuber J, Bormann J, Hubers M, et al. Effects of the lamino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991; 206 (4): 297-300
194. Erdo SL, Schafer M. Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. Eur J Pharmacol 1991; 198 (2-3): 215-7
195. Marvanova M, Lakso M, Pirhonen J, et al. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci 2001; 18 (3): 247-58
196. Storch A, Burkhardt K, Ludolph AC, et al. Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J Neurochem 2000; 75 (6): 2259-69
197. Araki T, Muramatsu Y, Tanaka K, et al. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice. Neurosci Lett 2001; 312 (1): 50-4
198. Obinu MC, Reibaud M, Blanchard V, et al. Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence. Mov Disord 2002; 17 (1): 13-9
199. Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 2002; 8 (4): 271-6
200. Riederer P, Sofic E, Rausch W, et al. Dopaminforschung heute und morgen- L-dopa in der zukunft. In: Riederer PUH, editor. L-dopa-substitution der Parkinson-krankheit. Vienna: Springer-Verlag, 1985: 127-44
201. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989; 52 (2): 381-9
202. Sofic E, Paulus W, Jellinger K, et al. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991; 56 (3): 978-82
203. Ostrerova-Golts N, Petrucelli L, Hardy J, et al. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 2000; 20 (16): 6048-54
204. Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 2001; 276 (14): 10737-44
205. Turnbull S, Tabner BJ, El-Agnaf OM, et al. alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic Biol Med 2001; 30 (10): 1163-70
206. Ebadi M, Govitrapong P, Sharma S, et al. Ubiquinone (coenzyme q 10) and mitochondria in oxidative stress of Parkinson's disease. Biol Signals Recept 2001; 10 (3-4): 224-53
207. Monteiro HP, Winterbourn CC. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem Pharmacol 1989; 38 (23): 4177-82
208. Mochizuki H, Imai H, Endo K, et al. Iron accumulation in the substantia nigra of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci Lett 1994; 168 (1-2): 251-3
209. Oestreicher E, Sengstock G J, Riederer P, et al. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 1994; 660 (1): 8-18
210. Temlett JA, Landsberg JP, Watt F, et al. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J Neurochem 1994; 62 (1): 134-46
211. Ben-Shachar D, Youdim MB. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem 1991; 57 (6): 2133-5
212. Levites Y, Weinreb O, Maor G, et al. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 2001; 78: 1073-82
213. LaVaute T, Smith S, Cooperman S, et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 2001; 27 (2): 209-14
214. Bruehlmeier M, Leenders KL, Vontobel P, et al. Increased cerebral iron uptake in Wilson's disease: a 52Fe-citrate PET study. J Nucl Med 2000; 41 (5): 781-7
215. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001; 28 (4): 350-4
216. Zhou B, Westaway SK, Levinson B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001; 28 (4): 345-9
217. Miyajima H, Takahashi Y, Kamata T, et al. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 1997; 41 (3): 404-7
218. Guo Q, Zhao B, Li M, et al. ESR study on the structure-antioxidant activity relationship of tea catechins and their epimers. Biochim Biophys Acta 1996; 1304 (3): 210-22
219. Suganuma M, Okabe S, Oniyama M, et al. Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis 1998; 19: 1771-6
220. Vatassery GT, Bauer T, Dysken M. High doses of vitamin E in the treatment of disorders of the central nervous system in the aged. Am J Clin Nutr 1999; 70 (5): 793-801
221. McCay PB. Vitamin E: interactions with free radicals and ascorbate. Annu Rev Nutr 1985; 5: 323-40
222. Hall ED, Yonkers PA, Andrus PK, et al. Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury. J Neurotrauma 1992; 9 Suppl. 2: S425-42
223. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997; 22 (1-2): 359-78
224. Behl C. Vitamin E protects neurons against oxidative cell death in vitro more effectively than 17-beta estradiol and induces the activity of the transcription factor NF-kappaB. J Neural Transm 2000; 107 (4): 393-407
225. Kilander L, Ohrvall M. Alpha-tocopherol and Alzheimer's disease. N Engl J Med 1997; 337 (8): 572-3
226. Dufresne C, Farnworth E. A review of latest research findings on the health promotion properties of tea. J Nutr Biochem 2001; 12 (7): 404-21
227. Schroeter H, Williams R J, Matin R, et al. Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein. Free Radic Biol Med 2000; 29 (12): 1222-33
228. Hibatallah J, Carduner C, Poelman MC. In-vivo and in-vitro assessment of the free-radical-scavenger activity of ginkgo flavone glycosides at high concentration. J Pharm Pharmacol 1999; 51 (12): 1435-40
229. Bastianetto S, Ramassamy C, Dore S, et al. The ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 2000; 12 (6): 1882-90
230. Bastianetto S, Zheng WH, Quirion R. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br J Pharmacol 2000; 131 (4): 711-20
231. Joseph JA, Shukitt-Hale B, Denisova NA, et al. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. J Neurosci 1999; 19 (18): 8114-21
232. Pratico D, Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med 2000; 109 (7): 577-85
233. Clostre F. Ginkgo biloba extract (EGb 761): state of knowledge in the dawn of the year 2000 [French]. Ann Pharm Fr 1999; 57 Suppl. 1: 1S8-88
234. Wang ZY, Huang MT, Lou YR, et al. Inhibitory effects of black tea, green tea, decaffeinated black tea, and decaffeinated green tea on ultraviolet B light-induced skin carcinogenesis in 7,12-dimethylbenz[a]anthracene-initiated SKH-1 mice. Cancer Res 1994; 54 (13): 3428-55
235. Haqqi TM, Anthony DD, Gupta S, et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci U S A 1999; 96 (8): 4524-9
236. Pan MH, Lin-Shiau SY, Ho CT, et al. Suppression of lypopolysaccharide-induced nuclear factor kappaB activity by theaflavin-3,3′-digallate from black tea and other polyphenols through down-regulation of IkappaB kinase activity in macrophages. 2000; 59 (12): 357-67
237. Lin YL, Tsai SH, Lin-Shiau SY, et al. Theaflavin-3,3′-digallate from black tea blocks the nitric oxide synthase by down-regulating the activation of NF-kappaB in macrophages. Eur J Pharmacol 1999; 367 (2-3): 379-88
238. Salah N, Miller NJ, Paganga G, et al. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch Biochem Biophy 1995; 322 (2): 339-46
239. Nanjo F, Goto K, Seto R, et al. Scavenging effects of tea catechins and their derivatives on 1,-diphenyl-2-picrylhydrazyl radical. Free Radic Biol Med 1996; 21 (6): 895-902
240. Morel I, Lescoat G, Cogrel P, et al. Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. Biochem Pharmacol 1999; 45 (1): 13-9
241. Guo Q, Zhao B, Li M, et al. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim Biophys Acta 1996; 1304 (3): 210-22
242. Grinberg LN, Newmark H, Kitrossky N, et al. Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem Pharmacol 1997; 54 (9): 973-8
243. Levites Y, Youdim MBH, Maor G, et al. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem Pharmacol 2002; 63 (1): 21-9
244. Levites Y, Amit T, Youdim MB, et al. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol, (-)-epigallocatechin-3-gallate neuroprotective action. J Biol Chem 2002 Aug 23; 277 (34): 30574-80
245. Matsuoka Y, Hasegawa H, Okuda S, et al. Ameliorative effects of tea catechins on active oxygen-related nerve cell injuries. J Pharmacol Exp Ther 1995; 274 (2): 602-8
246. Lee S, Suh S, Kim S. Protective effects of the green tea polyphenol (-)-epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci Lett 2000; 287 (3): 191-4
247. van Acker SA, van den Berg D J, Tromp MN, et al. Structural aspects of antioxidant activity of flavonoids. Free Radic Biol Med 1996; 20 (3): 331-42
248. Checkoway H, Powers K, Smith-Weller T, et al. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002; 155 (8): 732-8
249. Hirsch EC, Hunot S, Damier P, et al. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 1998; 44 (3 Suppl. 1): S115-20
250. Luo Y, Umegaki H, Wang X, et al. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J Biol Chem 1998; 273 (6): 3756-64
251. Oo TF, Henchcliffe C, James D, et al. Expression of c-fos, cjun, and c-jun N-terminal kinase (JNK) in a developmental model of induced apoptotic death in neurons of the substantia nigra. J Neurochem 1999; 72 (2): 557-64
252. Perez-Otano I, Mandelzys A, Morgan JI. MPTP-Parkinsonism is accompanied by persistent expression of a delta-FosB-like protein in dopaminergic pathways. Brain Res Mol Brain Res 1998; 53 (1-2): 41-52
253. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neuro-degenerative diseases. Brain Res Brain Res Rev 1995; 21 (2): 195-218
254. Adams J, Collaco-Moraes Y, de Belleroche J. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem 1996; 66 (1): 6-13
255. Westwick JK, Weitzel C, Minden A, et al. Tumor necrosis factor alpha stimulates AP-I activity through prolonged activation of the c-Jun kinase. J Biol Chem 1994; 269 (42): 26396-401
256. Yamamoto K, Arakawa T, Ueda N, et al. Transcriptional roles of nuclear factor kappab and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 1995; 270 (52): 31315-20
257. Aubin N, Curet O, Deffois A, et al. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 1998; 71 (4): 1635-42
258. Ferger B, Teismann P, Earl CD, et al. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol 1999; 360 (3): 256-61
259. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-I and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001; 39 (2): 167-74
260. Grilli M, Pizzi M, Memo M, et al. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 1996; 274 (5291): 1383-5
261. Amin AR, Vyas P, Attur M, et al. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci U S A 1995; 92 (17): 7926-30
262. Casper D, Yaparpalvi U, Rempel N, et al. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett 2000; 289 (3): 201-4
263. Jackson LM, Hawkey CJ. COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages? Drugs 2000; 59 (6): 1207-16
264. Heinemann S, Boulter J, Connolly J, et al. The nicotinic receptor genes. Clin Neuropharmacol 1991; 14 Suppl. 1: S45-61
265. Anand R, Conroy WG, Schoepfer R, et al. Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. J Biol Chem 1991; 266 (17): 11192-8
266. Wonnacott S, Irons J, Rapier C, et al. Presynaptic modulation of transmitter release by nicotinic receptors. Prog Brain Res 1989; 79: 157-63
267. Rowell PP, Winkler DL. Nicotinic stimulation of [3H]acetylcholine release from mouse cerebral cortical synaptosomes. J Neurochem 1984; 43 (6): 1593-8
268. Quirion R, Richard J, Wilson A. Muscarinic and nicotinic modulation of cortical acetylcholine release monitored by in vivo microdialysis in freely moving adult rats. Synapse 1994; 17 (2): 92-100
269. Whitehouse PJ, Hedreen JC, White III CL, et al. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983; 13 (3): 243-8
270. Perry EK, Curtis M, Dick D J, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48 (5): 413-21
271. Whitehouse PJ, Martino AM, Marcus KA, et al. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 1988; 45 (7): 722-4
272. Baron J. Epidemiology of smoking and Parkinson's disease [abstract]. In: Clarke P, Quik M, Thurau K, et al., editors. Effects of nicotine on biological systems II. Boston: Birkhauser, 1994: s42
273. Allam MF. Transdermal nicotine in PD: a randomized, doubleblind, placebo-controlled study [letter]. Neurology 2002; 58 (7): 1133
274. Mitsuoka T, Kaseda Y, Yamashita H, et al. Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism. Hiroshima J Med Sci 2002; 51 (1): 33-9
275. Morens DM, Grandinetti A, Reed D, et al. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995; 45 (6): 1041-51
276. Paulson GW. Addiction to nicotine is due to high intrinsic levels of dopamine. Med Hypotheses 1992; 38 (3): 206-7
277. Zheng JQ, Felder M, Connor JA, et al. Turning of nerve growth cones induced by neurotransmitters. Nature 1994; 368 (6467): 140-4
278. Hedin CA. Smoker's melanosis may explain the lower heating loss and lower frequency of Parkinson's disease found among tobacco smokers: a new hypothesis. Med Hypotheses 1991; 35 (3): 247-9
279. Gresham LS, Molgaard CA, Smith RA. Induction of cytochrome P-450 enzymes via tobacco smoke: a potential mechanism for developing resistance to environmental toxins as related to parkinsonism and other neurologic diseases. Neuroepidemiology 1993; 12 (2): 114-6
280. Yong VW, Perry TL. Monoamine oxidase B, smoking, and Parkinson's disease. J Neurol Sci 1986; 72 (2-3): 265-72
281. Quik M, Jeyarasasingam G. Nicotinic receptors and Parkinson's disease. Eur J Pharmacol 2000; 393 (1-3): 223-30
282. Jeyarasasingam G, Tompkins L, Quik M. Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience 2002; 109 (2): 275-85
283. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, et al. Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. Biochem Pharmacol 2002; 64 (1): 125-35
284. Janson AM, Meana JJ, Goiny M, et al. Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the mesodiencephalic junction in rats: a microdialysis study. Neurosci Lett 1991; 134 (1): 88-92
285. Janson AM, Fuxe K, Agnati LF, et al. Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Res 1988; 455 (2): 332-45
286. Janson AM, Fuxe K, Sundstrom E, et al. Chronic nicotine treatment partly protects against the 1-methyl-4- phenyl-2,3,6tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand 1988; 132 (4): 589-91
287. Ryan RE, Ross SA, Drago J, et al. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol 2001; 132 (8): 1650-6
288. Bannon AW, Decker MW, Holladay MW, et al. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 1998; 279 (5347): 77-81
289. Lloyd GK, Menzaghi F, Bontempi B, et al. The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci 1998; 62 (17-18): 1601-6
290. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290 (5492): 767-73
291. Palfi S, Leventhal L, Chu Y, et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 2002; 22 (12): 4942-54
292. Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999; 46 (3): 419-24
293. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9 (5): 589-95
294. Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol 2003; 53 Suppl. 3: S39-47; discussion S47-8
295. Kitamura Y, Itano Y, Kubo T, et al. Suppressive effect of FK506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. J Neuroimmunol 1994; 50 (2): 221-4
296. Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl (R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-I (R)-aminoindan. J Neurochem 2002; 82 (4): 913-23
297. Kaminski Schierle GS, Hansson O, Brundin P. Flunarizine improves the survival of grafted dopaminergic neurons. Neuroscience 1999; 94 (1): 17-20
298. Terland O, Flatmark T. Drug-induced parkinsonism: cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles. Neuropharmacology 1999; 38 (6): 879-82
299. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 2000; 97 (6): 2875-80
300. Robertson GS, Crocker S J, Nicholson DW, et al. Neuroprotection by the inhibition of apoptosis. Brain Pathol 2000; 10 (2): 283-92
301. Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X (L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8 (3): 705-11
302. Hartmann A, Troadec JD, Hunot S, et al. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 2001; 21 (7): 2247-55
303. Mechoulam R. The pharmacohistory of cannabis sativa. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC, 1986: 1-19
304. Annas GJ. Reefer madness: the federal response to California's medical-marijuana law. N Engl J Med 1997; 337 (6): 435-9
305. Mechoulam R, Vogel Z, Barg J. CNS cannabinoid receptors: role and therapeutic implications for CNS disorders. CNS Drugs 1994; 2 (4): 255-60
306. Devane WA. New dawn of cannabinoid pharmacology. Trends Pharmacol Sci 1994; 15 (2): 40-1
307. Devane WA, Dysarz III FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34 (5): 605-13
308. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258 (5090): 1946-9
309. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50 (1): 83-90
310. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215 (1): 89-97
311. Di Marzo V, Melck D, Bisogno T, et al. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998; 21 (12): 521-8
312. Herkenham M, Lynn AB, de Costa BR, et al. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991; 547 (2): 267-74
313. Glass M, Brotchie JM, Maneuf YP. Modulation of neurotransmission by cannabinoids in the basal ganglia. Eur J Neurosci 1997; 9 (2): 199-203
314. Romero J, Garcia L, Cebeira M, et al. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sci 1995; 56 (23-24): 2033-40
315. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74 (2): 129-80
316. Jeon YJ, Yang KH, Pulaski JT, et al. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydro-cannabinol is mediated through the inhibition of nuclear factor-kappa B/Rel activation. Mol Pharmacol 1996; 50 (2): 334-41
317. Skaper SD, Buriani A, Dal Toso R, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A 1996; 93 (9): 3984-9
318. Hampson AJ, Bornheim LM, Scanziani M, et al. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 1998; 70 (2): 671-6
319. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 1998; 54 (3): 459-62
320. Hampson A J, Grimaldi M, Axelrod J, et al. Cannabidiol and (-)delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998; 95 (14): 8268-73
321. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001; 298 (1): 7-14
322. Meschler JP, Howlett AC, Madras BK Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berl) 2001; 156 (1): 79-85
323. Frankel JP, Hughes A, Lees AJ, et al. Marijuana for parkinsonian tremor [letter]. J Neurol Neurosurg Psychiatry 1990; 53 (5): 436
324. Commins DL, Vosmer G, Virus RM, et al. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987; 241 (1): 338-45
325. Schmidt CJ. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 1987; 240 (1): 1-7
326. Logan BJ, Laverty R, Sanderson WD, et al. Differences between rats and mice in MDMA (methylenedioxymethy-lamphetamine) neurotoxicity. Eur J Pharmacol 1988; 152 (3): 227-34
327. O'Callaghan JP, Miller DB. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994; 270 (2): 741-51
328. Stone DM, Stahl DC, Hanson GR, et al. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 1986; 128 (1-2): 41-8
329. Nash JF, Nichols DE. Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. Eur J Pharmacol 1991; 200 (1): 53-8
330. Ecstasy & agony [online]. Available from URL: http://www.bbc.co.uk/science/horizon/2000/ecstasyagony.shtml [Accessed 10 April 2003]
331. Ricaurte GA, Yuan J, Hatzidimitriou G, et al. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("Ecstasy"). Science 2002; 297 (5590): 2260-3
332. von Sydow K, Lieb R, Pfister H, et al. Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults-a transient phenomenon? Results from a longitudinal community study. Drug Alcohol Depend 2002; 66 (2): 147-59
333. Youdim MB, Lavie L. Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease. Life Sci 1994; 55 (25-26): 2077-82
334. Colangelo V, Schurr J, Ball MJ, et al. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 2002; 70 (3): 462-73
335. Jin K, Mao XO, Eshoo MW, et al. Microarray analysis of hippocampal gene expression in global cerebral ischemia. Ann Neurol 2001; 50 (1): 93-103
336. Aronowski J, Strong R, Shirzadi A, et al. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke 2003; 34 (5): 1246-51